Review article: Inflammatory bowel disease and genetics

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue SUPPL. 2, 2007, Pages 57-65

  Weersma, R K ^a   Van Dullemen, H M ^a   Van Der Steege, G ^a   Nolte, I M ^a   Kleibeuker, J H ^a   Dijkstra, G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 4; ORGANIC CATION TRANSPORTER 5; PROTEIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL MODEL; CHROMOSOME 5Q; CHROMOSOME 5Q31; CHROMOSOME 5Q32; CHROMOSOME 5Q33; CHROMOSOME 6P; CONFERENCE PAPER; CROHN DISEASE; ENTERITIS; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETICS; HLA SYSTEM; HUMAN; NONHUMAN; PRIORITY JOURNAL; ULCERATIVE COLITIS;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; NOD1 SIGNALING ADAPTOR PROTEIN; NOD2 SIGNALING ADAPTOR PROTEIN; TOLL-LIKE RECEPTOR 4;

EID: 36849020975     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03476.x     Document Type: Conference Paper

References (89)

1. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996 379 : 821 3.
2. Cho JH, Nicolae DL, Gold LH, et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epitasis between 1p and IBD1. Proc Natl Acad Sci U S A 1998 95 : 7502 7.
3. Duerr RH, Barmada MM, Zhang L, Pfutzer R, Weeks DE. High-density genome scan in Crohn disease shows confirmed linkage to chromosome 14q11-12. Am J Hum Genet 2000 66 : 1857 62.
4. Hampe J, Schreiber S, Shaw SH, et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 1999 64 : 808 16.
5. Ma Y, Ohmen JD, Li Z, Bentley LG. A genome-wide search identifies potential new susceptibility loci for Crohn's disease. Inflamm Bowel Dis 1999 5 : 271 8.
6. Williams CN, Kocher K, Lander ES, et al. Using a genome-wide scan and meta-analysis to identify a novel IBD locus and confirm previously identified IBD loci. Inflamm Bowel Dis 2002 8 : 375 81.
7. Paavola-Sakki P, Ollikainen V, Helio T, et al. Genome-wide search in Finnish families with inflammatory bowel disease provides evidence for novel susceptibility loci. Eur J Hum Genet 2003 11 : 112 20.
8. Vermeire S, Rutgeerts P, Van Steen K, et al. Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut 2004 53 : 980 6.
9. Rioux JD, Silverberg MS, Daly MJ, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000 66 : 1863 70.
10. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996 14 : 199 202.
11. Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001 29 : 223 8.
12. Barmada MM, Brant SR, Nicolae DLA, et al. Genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis 2004 10 : 15 22.
13. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001 411 : 603 6.
14. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001 411 : 599 603.
15. Oostenbrug LE, Drenth JP, de Jong DJ, et al. Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis 2005 11 : 567 75.
16. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003 124 : 26 33.
17. McGovern DP, Hysi P, Ahmad T, et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 2005 14 : 1245 50.
18. De la Concha EG, Fernandez-Arquero M, Lopez-Nava G, et al. Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. Gastroenterology 2000 119 : 1491 5.
19. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004 36 : 476 80.
20. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004 36 : 471 5.
21. Eckmann L, Karin M. NOD2 and Crohn's disease: loss or gain of function? Immunity 2005 22 : 661 7.
22. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001 276 : 4812 8.
23. Ogura Y, Lala S, Xin W, et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003 52 : 1591 7.
24. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002 122 : 854 66.
25. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004 99 : 2393 404.
26. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001 29 : 19 20.
27. Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005 307 : 734 8.
28. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004 5 : 800 8.
29. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005 307 : 731 4.
30. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005 102 : 18129 34.
31. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004 53 : 1658 64.
32. Chamaillard M, Hashimoto M, Horie Y, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003 4 : 702 7.
33. Zouali H, Lesage S, Merlin F, et al. CARD4/NOD1 is not involved in inflammatory bowel disease. Gut 2003 52 : 71 4.
34. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005 54 : 1182 93.
35. Hausmann M, Kiessling S, Mestermann S, et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002 122 : 1987 2000.
36. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998 282 : 2085 8.
37. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999 274 : 10689 92.
38. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000 25 : 187 91.
39. Gazouli M, Mantzaris G, Kotsinas A, et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 2005 11 : 681 5.
40. Ouburg S, Mallant-Hent R, Crusius JB, et al. The toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localisation of Crohn's disease without a major role for the Saccharomyces cerevisiae mannan-LBP-CD14-TLR4 pathway. Gut 2005 54 : 439 40.
41. Franchimont D, Vermeire S, El HH, Pierik M, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis Gut 2004 53 : 987 92.
42. Török HP, Glas J, Tonenchi L, et al. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004 112 : 85 91.
43. Lakatos PL, Lakatos L, Szalay E, et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol 2005 11 : 1489 95.
44. Pierik M, Joossens S, Van Steen K., et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006 12 : 1 8.
45. van Heel DA, Fisher SA, Kirby A, et al. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 2004 13 : 763 70.
46. The MHC sequencing consortium. Complete sequence and gene map of a human major histocompatibility complex. Nature 1999 401 : 921 3.
47. Jardetzky TS, Brown JH, Gorga JC, et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994 368 : 711 8.
48. Yap LM, Ahmad T, Jewell DP. The contribution of HLA genes to IBD susceptibility and phenotype. Best Pract Res Clin Gastroenterol 2004 18 : 577 96.
49. Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 1999 45 : 395 401.
50. Silverberg MS, Mirea L, Bull SB, et al. A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease. Inflamm Bowel Dis 2003 9 : 1 9.
51. Myung SJ, Yang SK, Jung HY, et al. HLA-DRB1*1502 confers susceptibility to ulcerative colitis, but is negatively associated with its intractability: a Korean study. Int J Colorectal Dis 2002 17 : 233 7.
52. Yoshitake S, Kimura A, Okada M, Yao T, Sasazuki T. HLA class II alleles in Japanese patients with inflammatory bowel disease. Tissue Antigens 1999 533 : 50 8.
53. Trachtenberg EA, Yang H, Hayes EHLA, et al. Class II haplotype associations with inflammatory bowel disease in Jewish(Ashkenazi) and non-Jewish caucasian populations. Hum Immunol 2000 61 : 326 33.
54. Newman B, Silverberg MS, Gu X, et al. CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease. Am J Gastroenterol 2004 99 : 306 15.
55. Fernandez L, Mendoza JL, Martinez A, et al. IBD1 and IBD3 determine location of Crohn's disease in the Spanish population. Inflamm Bowel Dis 2004 10 : 715 22.
56. Neurath MF, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997 27 : 1743 50.
57. Noguchi M, Hiwatashi N, Liu Z, et al. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998 43 : 203 9.
58. Van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995 109 : 129 35.
59. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337 : 1029 35.
60. O'Callaghan NJ, Adams KE, van Heel DA, Cavanaugh JA. Association of TNF-alpha-857C with inflammatory bowel disease in the Australian population. Scand J Gastroenterol 2003 38 : 533 4.
61. Negoro K, Kinouchi Y, Hiwatashi N, et al. Crohn's disease is associated with novel polymorphisms in the 5'-flanking region of the tumor necrosis factor gene. Gastroenterology 1999 117 : 1062 8.
62. Yamazaki K, McGovern D, Ragoussis J, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005 14 : 3499 506.
63. Migone TS, Zhang J, Luo X, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002 16 : 479 92.
64. Ahmad T, Neville M, Marshall SE, et al. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet 2003 12 : 647 56.
65. Newman B, Gu X, Wintle R, et al. A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. Gastroenterology 2005 128 : 260 9.
66. Torok HP, Glas J, Tonenchi L, et al. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut 2005 54 : 1421 7.
67. Armuzzi A, Ahmad T, Ling KL, et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 2003 52 : 1133 9.
68. Vermeire S, Pierik M, Hlavaty T, et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. Gastroenterology 2005 129 : 1845 53.
69. Noble CL, Nimmo ER, Drummond H, et al. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology 2005 129 : 1854 64.
70. Wakabayashi M, Ito T, Mitsushima M, et al. Interaction of lp-dlg/KIAA0583, a membrane-associated guanylate kinase family protein, with vinexin and beta-catenin at sites of cell-cell contact. J Biol Chem 2003 278 : 21709 14.
71. Friedrichs F, Brescianini S, Annese V, et al. Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. Hum Genet 2006 119 : 305 11.
72. Yamazaki K, Takazoe M, Tanaka T, et al. Association analysis of SLC22A4, SLC22A5 and DLG5 in Japanese patients with Crohn disease. J Hum Genet 2004 49 : 664 8.
73. Buning C, Geerdts L, Fiedler T, et al. DLG5 variants in inflammatory bowel disease. Am J Gastroenterol 2006 101 : 786 92.
74. Noble CL, Nimmo ER, Drummond H, et al. DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population. Gut 2005 54 : 1416 20.
75. Tremelling M, Waller S, Bredin F, et al. Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. Inflamm Bowel Dis 2006 12 : 178 84.
76. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003 52 : 759 66.
77. Panwala CM, Jones JC, Viney JL, et al. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998 161 : 5733 44.
78. Ho GT, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 2005 128 : 288 96.
79. Potocnik U, Ferkolj I, Glavac D, et al. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun 2004 5 : 530 9.
80. Brant SR, Panhuysen CI, Nicolae D, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 2003 73 : 1282 92.
81. Croucher PJ, Mascheretti S, Foelsch UR, et al. Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastroenterology 2003 125 : 1919 20.
82. Glas J, Torok HP, Schiemann U, et al. MDR1 gene polymorphism in ulcerative colitis. Gastroenterology 2004 126 : 367.
83. Oostenbrug LE, Dijkstra G, Nolte IM, et al. Absence of association between the Multidrug Resistance (MDR)1 gene and inflammatory bowel disease. Scand J Gastroenterol 2006 41 : 1174 82.
84. Cummings JR, Jewell DP. Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm Bowel Dis 2005 11 : 56 61.
85. Reumaux D, Sendid B, Poulain D, Duthilleul P, Dewit O, Colombel JF. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 2003 17 : 19 35.
86. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000 6 : 8 15.
87. Oostenbrug LE, van Dullemen HM, te Meerman GJ, et al. Clinical outcome of Crohn's disease according to the Vienna classification: disease location is a useful predictor of disease course. Eur J Gastroenterol Hepatol 2006 18 : 255 61.
88. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005 19 (Suppl. A 5 36.
89. Sachar DB, Bodian CA, Goldstein ES, et al. Task Force on Clinical Phenotyping of the IOIBD. Is perianal Crohn's disease associated with intestinal fistulization? Am J Gastroenterol 2005 100 : 1547 9.